iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Traditional earnings payout ratios favor Novo Nordisk, but cash-dividend coverage points the other way. In the Motley Fool article dated October 4, 2026, Reuben Gregg Brewer reports an earnings payout ratio of 33% for Novo Nordisk versus 220% for Pfizer, alongside cash-dividend payout ratios of about 110% and 90%, respectively. Those figures use a different measure and their exact calculation periods and inputs are not stated, so they should be read as the article’s snapshot—not as independently reconciled current ratios. (Motley Fool)
The comparison’s practical lesson is that an earnings payout ratio alone cannot establish dividend safety. Brewer reports a higher yield for Pfizer, but also describes significant risks at both companies. Whether one looks more attractive depends on cash generation and business risks as well as the headline yield.
What the payout ratios say—and what they don’t
A payout ratio compares a dividend with a financial measure, but its meaning depends on the denominator. An earnings-based ratio compares dividends with earnings; a cash-based ratio compares dividends with cash flow. They answer related but different questions, and figures calculated over different periods or using different definitions cannot be compared as if they were one consistent test.
| Measure | Pfizer | Novo Nordisk | How to read it |
|---|---|---|---|
| Earnings payout ratio reported in Brewer’s October 4, 2026 article | 220% | 33% | The article’s snapshot; the exact period and calculation inputs are not stated. A ratio above 100% means the reported dividend exceeded the earnings measure used in that calculation. |
| Cash-dividend payout ratio reported in the same article | About 90% | About 110% | The article’s snapshot; the exact cash-flow period and formula are not stated. A ratio above 100% means dividends exceeded the cash-flow measure used in that calculation. |
| Company-reported annual dividend payout ratio for 2025 | Not stated in the cited 2025 figures | 50.7% | Novo Nordisk’s 2025 annual-report figure, using the company’s definition; it is not automatically equivalent to the article’s cash-dividend ratio. (Novo Nordisk 2025 Annual Report) |
The apparent reversal is the comparison’s central tension: earnings favor Novo, while the article’s cash measure favors Pfizer. The figures do not prove that Pfizer’s dividend is safer. A cash payout above 100% can be sustained for a time using cash balances, borrowing, or other sources, but it raises the question of whether ongoing cash generation can support distributions. Conversely, a high earnings payout ratio does not by itself show that a dividend must be cut, particularly if earnings are depressed or do not track cash generation in the same period.
#1 Best Overall
What the 2025 company figures add
Company-reported full-year figures provide dated context, but do not independently reproduce the Motley Fool article’s payout-ratio calculations. Keep these annual results separate from its snapshot ratios.
Novo Nordisk
- Novo Nordisk reported total dividends of DKK 11.70 per share for 2025 and a 50.7% dividend payout ratio in its annual report. Its AGM announcement subsequently confirmed the 2025 distribution. (2025 Annual Report) (March 26, 2026 AGM announcement)
- The company reported free cash flow of DKK 28.3 billion for 2025. That figure is a company-reported annual result, not the denominator established for the article’s roughly 110% cash-dividend payout ratio. The annual report also notes a substantial prior-year acquisition effect, which matters when interpreting year-to-year free-cash-flow comparisons. (2025 Annual Report)
Pfizer
- Pfizer reported 2025 revenue of $62.579 billion, net cash provided by operating activities of $11.704 billion, and cash dividends paid of $9.771 billion. (Pfizer 2025 annual report)
- These figures show that dividends represented a substantial cash outlay relative to operating cash flow in 2025. They do not, by themselves, establish the roughly 90% cash-dividend payout ratio in Brewer’s article: the article’s exact formula and period are not stated, and its ratio should not be silently replaced by a new calculation from annual totals.
Yield is a moving snapshot, not a safety score
Brewer’s article reports yields of 6% for Pfizer and 4.7% for Novo Nordisk, dated to its October 4, 2026 publication. Yield changes as a share price moves and as a company changes its declared dividend; it is not a fixed company characteristic. (Motley Fool)
Rank #2
The higher reported Pfizer yield means a larger indicated income return at the prices and dividend assumptions behind that snapshot. It does not mean the dividend is more dependable. Investors comparing yields should check the current share price, the latest declared dividend, and whether the cash flow supporting that dividend appears sustainable.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallOutdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchThe business risks behind the numbers
Dividend capacity depends on the businesses producing the cash. Brewer characterizes Novo Nordisk as more concentrated in its core drug categories and in a shift toward volume, while describing Pfizer as having a broader portfolio but facing patent expirations and the challenge of replacing revenue through its pipeline. These are the Motley Fool author’s qualitative assessments in the dated article, not a fresh verification of current product, patent, or pipeline developments. (Motley Fool)
- Novo Nordisk: Concentration can make results more sensitive to changes affecting its core categories; execution as the business shifts toward volume is another consideration identified by the article.
- Pfizer: A broader portfolio spreads exposure across more products, but expiring patents can reduce sales and leave the company dependent on successful pipeline replacement, as the article notes.
Neither company’s payout ratio captures these risks. For an investment decision, the relevant question is whether future cash generation can cover dividends while also meeting operating, investment, debt, and pipeline needs—not simply which company has the lower earnings ratio today.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to use the comparison
- Check the date and definition. Treat the article’s yields and payout ratios as its October 4, 2026 snapshot. Before relying on a ratio, identify its dividend numerator, earnings or cash-flow denominator, and measurement period.
- Keep unlike measures separate. Do not substitute Novo Nordisk’s 2025 company-reported 50.7% payout ratio for the article’s cash-dividend ratio, or treat Pfizer’s 2025 cash totals as a direct confirmation of the article’s figure.
- Look beyond the distribution. Assess the cash left for business investment and other obligations, and consider the company-specific portfolio, patent, competition, and execution risks described in the article.
- Decide what matters most to you. The article’s higher Pfizer yield may appeal to an income-focused investor, while Novo’s lower reported earnings payout ratio may look more comfortable on that one measure. Neither observation is a standalone case for buying either stock.
This is a comparison of the Motley Fool author’s dated analysis and company-reported historical results, not individualized investment advice or a claim that either dividend is guaranteed.
Quick Recap
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
